Clinical trials
Influenza, Human trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Unknown status | 4 |
| Recruiting | 3 |
| Terminated | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 10 |
| GlaxoSmithKline | 7 |
| Seqirus | 5 |
| Wroclaw Medical University | 4 |
| Novartis Vaccines | 3 |
| Sanofi Pasteur, a Sanofi Company | 3 |
| Alachua Government Services, Inc. | 2 |
| Novartis | 2 |
| AstraZeneca | 1 |
| BioCryst Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Influenza, Human | 49 |
| COVID-19 | 3 |
| Cough | 2 |
| Fever | 2 |
| Headache | 2 |
| Heart Failure | 2 |
| Infections | 2 |
| Nasal Obstruction | 2 |
| Orthomyxoviridae Infections | 2 |
| Pharyngitis | 2 |
Trials
Showing 76 to 49 of 49. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.